Anti-Saccharomyces cerevisiae antibodies in acute myocardial infarction

Basit Öğe Kaydı
dc.contributor.authorCinemre, Hakan
dc.contributor.authorBilir, Cemil
dc.contributor.authorGökosmanoğlu, Feyzi
dc.contributor.authorKadakal, Figen
dc.date.accessioned2020-04-30T22:39:30Z
dc.date.available2020-04-30T22:39:30Z
dc.date.issued2007
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionBilir, Cemil/0000-0002-1372-4791en_US
dc.descriptionWOS: 000253218500016en_US
dc.descriptionPubMed: 18163971en_US
dc.description.abstractBackground: Elevated anti-Saccharomyces cerevisiae antibody (ASCA) immunoglobulin (IgG) and IgA levels were first described in the serum of Crohn disease patients and have increasingly been reported in other inflammatory diseases. The role of in situ and remote inflammation in atherosclerosis is a major area of interest. In this study, we compared ASCA IgG and IgA levels in acute myocardial infarction (AMI) and controls to investigate the possible role of ASCA in AMI. Methods: Serum samples were obtained from 140 consecutive patients who presented to the emergency department with acute chest pain. AMI was diagnosed by electrocardiography and serial enzymes. Patients ruled out for acute coronary event were grouped as controls. ASCA IgA and IgG levels were determined using enzyme-linked immunosorbent assay. Groups were compared for statistically significant difference. Results:ASCA IgG titers ranged between 0.1 and 31.0 RIU/mL (mean 4.92) in the AMI group and 0.1 and 6.0 (mean 0.84) in the controls. The groups were found to differ very significantly (p = .001). ASCA IgA titers ranged between 2.0 and 200.0 RIU/mL (mean 13.73) in the AMI group and 2.0 and 11.5 RIU/mL, (mean 4.25) in controls. The groups differed significantly (p = .32). AMI and controls were also analyzed for ASCA IgA and IgG positivity. Both groups differed significantly from controls (p = .013). Conclusion: Elevated ASCA IgA and IgG levels as well as ASCA positivity in the AMI might suggest use of ASCA as a marker for atherosclerotic plaque instability. It might also provide a link between inflammatory processes and increased cardiovascular risk. Further studies are needed on a Saccharomyces cerevisiae-based diet, related intestinal colonization, and associated inflammation, autoimmune disorders, and cardiovascular events.en_US
dc.identifier.doi10.2310/6650.2007.00024en_US
dc.identifier.endpage449en_US
dc.identifier.issn1081-5589
dc.identifier.issn1708-8267
dc.identifier.issue8en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage444en_US
dc.identifier.urihttps://doi.org/10.2310/6650.2007.00024
dc.identifier.urihttps://hdl.handle.net/20.500.12684/2742
dc.identifier.volume55en_US
dc.identifier.wosWOS:000253218500016en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherBmj Publishing Groupen_US
dc.relation.ispartofJournal Of Investigative Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleAnti-Saccharomyces cerevisiae antibodies in acute myocardial infarctionen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
2742.pdf
Boyut:
186.7 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu